Kappa antagonist effects of buprenorphine in the rat drug-discrimination procedure.
Negus
S S
SS
Dept. of Psychology, University of North Carolina, Chapel Hill 27514.
Picker
M J
MJ
Dykstra
L A
LA
D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D000700:Analgesics; D000818:Animals; D001921:Brain / Q000187:drug effects*; D002047:Buprenorphine / Q000494:pharmacology*; D004193:Discrimination Learning / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005283:Fentanyl / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology; D010470:Perceptual Masking; D011759:Pyrrolidines / Q000037:antagonists & inhibitors*; D051381:Rats; D011957:Receptors, Opioid / Q000187:drug effects*; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu
D000700:Analgesics; D011759:Pyrrolidines; D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D002047:Buprenorphine; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D009020:Morphine; D005283:Fentanyl